GUARDANT HEALTH, INC. vs NATERA, INC., two Medical Diagnostics stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Guardant and Natera are the same wager at different stages: molecular screening franchises spending through their income statements toward dominance, Guardant in cancer detection at a negative 40.2% operating margin, Natera in prenatal-and-oncology testing at negative 13.4%, further along the curve toward break-even. The market prices progress steeply: $37B for Natera against $20B for Guardant, nearly double for the smaller loss. Both balance sheets hold defensive liquidity and negligible debt; neither returns meaningful cash. No multiples exist on either page. The pair asks one question twice: how much is a diagnostics land-grab worth before the land pays rent? The market's two answers differ mainly by how close the rent sounds.
Comparison updated 2026-07-10.
| Metric | GH | NTRA |
|---|---|---|
| Price | $149.32 | $260.64 |
| Market cap | $19.6B | $36.9B |
| Sector | Medical Diagnostics | Medical Diagnostics |
| Stage | Growth | Growth |
| P/B | — | 20.79 |
| P/S | 18.15 | 14.75 |
| Revenue growth | +39.3% | +36.4% |
| Operating margin | -40.2% | -13.4% |
| Net margin | -40.1% | -9.1% |
| Return on equity | — | -12.8% |
| Return on assets | -22.6% | -8.7% |
| Return on invested capital | -26.7% | -13.8% |
| FCF yield | -1.2% | 0.3% |
| Debt / equity | — | 0.05 |
| Current ratio | 4.68 | 2.96 |
| Altman Z (solvency) | 4.37 | 5.81 |
| Piotroski F (quality) | 3 / 9 | 4 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.